We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Mass Cytometry Profiles to Aid Drug Development

By LabMedica International staff writers
Posted on 15 May 2017
Print article
Image: Fluorescent imaging of a tumor section identifies different types of macrophages (green) and T-cells (blue) present in the microenvironment of renal cell carcinoma (Photo courtesy of Karina Silina, University of Zurich).
Image: Fluorescent imaging of a tumor section identifies different types of macrophages (green) and T-cells (blue) present in the microenvironment of renal cell carcinoma (Photo courtesy of Karina Silina, University of Zurich).
Cancer researchers used a novel mass cytometry technique to reveal potential biomarkers for detection of renal cell carcinoma and to identify targets for development of immunotherapeutic agents to treat this essentially incurable disease.

Renal cell carcinoma (ccRCC) is a common and lethal uro-genital cancer. Around 50% of ccRCC patients develop metastases despite treatment, and less than 10% of these patients survive five years. Targeted treatments such as tyrosine kinase inhibitors do not cure the disease, but novel checkpoint immunotherapies have shown considerable promise in some patients. Thus, new avenues to guide immunotherapy-based treatments are urgently needed.

Towards this end, investigators at the University of Zurich used mass cytometry with extensive antibody panels to perform in-depth immune profiling of samples from 73 ccRCC patients and five healthy controls. Mass cytometry enabled the quantification of more than 50 readouts at the single-cell level by combining metal isotope-labeled antibodies with mass spectrometry detection. With its ability to analyze millions of cells in a short time at low cost, mass cytometry represents the method of choice to assess the phenotypic diversity of T-cells and tumor-associated macrophages (TAMs) present in the tumor microenvironment in large patient cohorts.

The investigators reported in the May 4, 2017, issue of the journal Cell that by screening 3.5 million cells, they had identified 17 tumor-associated macrophage phenotypes and 22 T-cell phenotypes. This data expanded the view of T-cell immunosuppression phenotypes, suggested links between a TAM phenotype and populations of regulatory T-cells and CD8+ immunosuppressed T-cells, and identified an immune cell composition within the tumor microenvironment that was correlated with progression-free survival.

"The previous picture of immune defense was correct, but coarse," said first author, Dr. Stéphane Chevrier, a researcher in the institute of molecular life sciences at the University of Zurich. "With our methods to analyze individual immune cells, we have been able to create an immunological atlas of the tumor environment for the first time with high resolution and in a large patient cohort. As a result, many more facets have now come to light."

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.